Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 99
Filter
1.
Curr Pharm Des ; 13(18): 1925-8, 2007.
Article in English | MEDLINE | ID: mdl-17584117

ABSTRACT

Agents suppressing microglial activation are attracting attention as candidate drugs for neuroprotection in Parkinson s disease (PD): While different mechanisms including environmental toxins and genetic factors initiate neuronal damage in the substantia nigra and striatum in PD, there is unequivocal evidence that activation of neuroinflammatory cells aggravates this neurodegenerative process. It was shown that following an acute exposure to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and other toxins the degenerative process continues for years in absence of the toxin. Reactive microglia has been observed in the substantia nigra of patients with PD, indicating that this inflammatory process might aggravate neurodegeneration. By releasing various kinds of noxious factors such as cytokines or proinflammatory molecules microglia may damage CNS cells. The stimuli triggering microgliosis in Parkinsonian syndromes are unknown so far: However, analysis of neuronal loss in PD patients shows that it is not uniform but that neurons containing neuromelanin (NM) are predominantly involved. We hypothesized that extraneuronal melanin might trigger microgliosis, microglial chemotaxis and microglial activation in PD with subsequent release of neurotoxic mediators. The addition of human NM to microglial cell cultures induced positive chemotactic effects, activated the pro-inflammatory transcription factor nuclear factor kappa B (NF-kappaB) via phosphorylation and degradation of the inhibitor protein kappaB (IkappaB), and led to an upregulation of TNF-alpha, IL-6 and NO. These findings demonstrate a crucial role of NM in the pathogenesis of Parkinson's disease by augmentation of microglial activation, leading to a vicious cycle of neuronal death, exposure of additional neuromelanin and chronification of inflammation. Antiinflammatory drugs may be one of the new approaches in the treatment of PD.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Inflammation/drug therapy , Melanins/metabolism , Microglia/drug effects , Neurodegenerative Diseases/drug therapy , Neurons/drug effects , Neuroprotective Agents/pharmacology , Substantia Nigra/drug effects , Animals , Anti-Inflammatory Agents/therapeutic use , Antiparkinson Agents/pharmacology , Cell Death/drug effects , Cytokines/metabolism , Humans , Inflammation/metabolism , Inflammation/pathology , Inflammation Mediators/metabolism , Microglia/metabolism , Microglia/pathology , Neurodegenerative Diseases/metabolism , Neurodegenerative Diseases/pathology , Neurons/pathology , Neuroprotective Agents/therapeutic use , Parkinson Disease/drug therapy , Substantia Nigra/metabolism , Substantia Nigra/pathology
2.
Neurology ; 67(7 Suppl 2): S8-11, 2006 Oct 10.
Article in English | MEDLINE | ID: mdl-17030740

ABSTRACT

In many parkinsonian syndromes, neuromelanin (NM)-containing dopaminergic neurons of the substantia nigra (SN) are selectively targeted by the noxius pathogens. Studies of the constitutional and functional features of human NM allow the formulation of a logical hypothesis on its role in parkinsonian syndromes. In the early stages, NM synthesis and iron-chelating properties may act as a powerful protective mechanism, delaying symptom appearance and/or slowing disease progression. Once these systems have been exhausted, the pathogenic mechanisms affecting cytoplasmic organelles other than NM destroy NM-harboring neurons, with consequent pouring out of NM granules. These in turn activate microglia, causing release of nitric oxide, interleukin-6 and tumor necrosis factor-alpha, thus becoming an important determinant of disease aggravation. Neuromelanin appears to be a suitable target for devising chemical agents that might modify the course of these diseases.


Subject(s)
Melanins/physiology , Parkinson Disease/etiology , Aging , Animals , Disease Progression , Humans , Melanins/biosynthesis , Melanins/chemistry
3.
J Neural Transm (Vienna) ; 113(6): 757-67, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16755380

ABSTRACT

In this study a comparative analysis of iron molecules during aging was performed in locus coeruleus (LC) and substantia nigra (SN), known targets of Parkinson's Disease (PD) and related disorders. LC and SN neurons, especially the SN pars compacta, degenerate in PD and other forms of parkinsonism. Iron and its major molecular forms, such as ferritin and neuromelanin (NM), were measured in LC and SN of normal subjects at various ages. Iron levels were lower, H-ferritin/iron ratio was higher and the iron content in NM was lower in LC than in SN. Iron deposits were abundant in SN tissue, very scarse in LC tissue and completely absent in pigmented neurons of both SN and LC. In both regions H- and L-ferritins were present only in glia. This suggests that in LC neurons iron mobilization and toxicity is lower than that in SN and is efficiently buffered by NM. Ferritins accomplish the same buffering function in glial cells.


Subject(s)
Aging , Iron/analysis , Locus Coeruleus/chemistry , Melanins/analysis , Neurons/chemistry , Substantia Nigra/chemistry , Adolescent , Adult , Aged , Aged, 80 and over , Female , Ferritins/analysis , Humans , Iron Chelating Agents/chemistry , Locus Coeruleus/cytology , Male , Middle Aged , Neuroglia/chemistry , Neuroglia/cytology , Neurons/cytology , Substantia Nigra/cytology
4.
Prog Neurobiol ; 78(6): 364-73, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16682109

ABSTRACT

Alzheimer's disease (AD) and Parkinson's disease (PD) share several pathological mechanisms. The parallels between amyloid beta (Abeta) in AD and alpha-synuclein in PD have been discussed in several reports. However, studies of the last few years show that Abeta also shares several important characteristics with neuromelanin (NM), whose role in PD is emerging. First, both molecules accumulate with aging, the greatest risk factor for AD and PD. Second, in spite of their different structures, Abeta and NM have similar characteristics that could also lead to neuroprotection. Metals are required to catalyze their formation and they can bind large amounts of these metals, generating stable complexes and thus playing a protective role against metal toxicity. Moreover, they may be able to remove toxic species such as oligopeptides and excess cytosolic dopamine. Third, both Abeta and NM have been implicated in parallel aspects of the neuronal death that underlies AD and PD, respectively. For example, both molecules can activate microglia, inducing release of toxic factors such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and nitric oxide (NO). A careful analysis of these parallel effects of Abeta and NM, including their seemingly paradoxical ability to participate in both cell death and protection, may lead to an improved understanding of the roles of these molecules in neurodegeneration and also provide insights into possible parallels in the pathological mechanisms underlying AD and PD.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Melanins/metabolism , Parkinson Disease/metabolism , Alzheimer Disease/pathology , Animals , Humans , Parkinson Disease/pathology
5.
Cell Mol Life Sci ; 62(2): 143-58, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15666086

ABSTRACT

Aluminium, an environmentally abundant non-redox trivalent cation has long been implicated in the pathogenesis of Alzheimer's disease (AD). However, the definite mechanism of aluminium toxicity in AD is not known. Evidence suggests that trace metal homeostasis plays a crucial role in the normal functioning of the brain, and any disturbance in it can exacerbate events associated with AD. The present paper reviews the scientific literature linking aluminium with AD. The focus is on aluminium levels in brain, region-specific and subcellular distribution, its relation to neurofibrillary tangles, amyloid beta, and other metals. A detailed mechanism of the role of aluminium in oxidative stress and cell death is highlighted. The importance of complex speciation chemistry of aluminium in relation to biology has been emphasized. The debatable role of aluminium in AD and the cross-talk between aluminium and genetic susceptibility are also discussed. Finally, it is concluded based on extensive literature that the neurotoxic effects of aluminium are beyond any doubt, and aluminium as a factor in AD cannot be discarded. However, whether aluminium is a sole factor in AD and whether it is a factor in all AD cases still needs to be understood.


Subject(s)
Aluminum/toxicity , Alzheimer Disease/etiology , Brain/drug effects , Aluminum/blood , Alzheimer Disease/chemically induced , Animals , Brain/physiopathology , Cell Death , Genetic Predisposition to Disease , Humans , Metals/toxicity , Neurofibrillary Tangles/metabolism , Oxidative Stress , Rats
6.
J Neural Transm (Vienna) ; 111(10-11): 1253-65, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15480837

ABSTRACT

Recently, impairment of the ubiquitin-proteasome system is suggested to be responsible for the neuronal death in ageing and Parkinson's disease. The specific degeneration of dopamine neurons containing neuromelanin (NM) suggests that NM itself may be involved in the cellular dysfunction and death, even though the direct link has never been reported. We examined the effects of NM isolated from the human substantia nigra on the proteasome activity in human dopaminergic SH-SY5Y cells. NM reduced the activities of 26S proteasome, as shown in situ using a green fluorescent protein homologue targeted to 26S proteasome and also in vitro using ubiquitinated lysozyme as a substrate. However, NM did not affect 20S proteasome activity in vitro. NM reduced the amount of PA700 regulatory subunit of 26S proteasome, but did not affect that of alpha- and beta-subunits of 20S proteasome. These results suggest that NM may inhibit the ubiquitin-26S proteasome system, and determine the selective vulnerability of dopamine neurons in ageing and related disorders.


Subject(s)
Dopamine/physiology , Melanins/pharmacology , Proteasome Inhibitors , Adult , Aging/physiology , Cell Death/physiology , Chymotrypsin/metabolism , Genetic Vectors , Green Fluorescent Proteins/metabolism , Humans , In Vitro Techniques , Microscopy, Phase-Contrast , Muramidase/metabolism , Ornithine Decarboxylase/metabolism , Parkinson Disease/metabolism , Proteasome Endopeptidase Complex , Spectrometry, Fluorescence , Ubiquitin/physiology
7.
J Neural Transm Suppl ; (65): 145-55, 2003.
Article in English | MEDLINE | ID: mdl-12946053

ABSTRACT

The pigmented neurons of the substantia nigra (SN) are typically lost in Parkinson's disease: however the possible relationship between neuronal vulnerability and the presence of neuromelanin (NM) has not been elucidated. Early histological studies revealed the presence of increasing amounts of NM in the SN with aging in higher mammals, showed that NM granules are surrounded by membrane, and comparatively evaluated the pigmentation of SN in different animal species. Histochemical studies showed the association of NM with lipofuscins. However, systematic investigations of NM structure, synthesis and molecular interactions have been undertaken only during the last decade. In these latter studies, NM was identified as a genuine melanin with a strong chelating ability for iron and affinity for compounds such as lipids, pesticides, and MPP+. The affinity of NM for a variety of inorganic and organic toxins is consistent with a postulated protective function for NM. Moreover, the neuronal accumulation of NM during aging, and the link between its synthesis and high cytosolic concentration of catechols suggests a protective role. However, its putative neuroprotective effects could be quenched in conditions of toxin overload.


Subject(s)
Aging/metabolism , Melanins/chemistry , Melanins/metabolism , Nerve Tissue Proteins/chemistry , Nerve Tissue Proteins/metabolism , Neurons/metabolism , Substantia Nigra/metabolism , Humans , Iron Chelating Agents/metabolism , Lipofuscin/metabolism , Melanins/biosynthesis , Nerve Tissue Proteins/biosynthesis , Neurons/pathology , Neuroprotective Agents/metabolism , Parkinson Disease/metabolism
8.
J Neurol ; 250(5): 556-60, 2003 May.
Article in English | MEDLINE | ID: mdl-12736734

ABSTRACT

Although genomic screening studies have identified several genes associated with Parkinson's disease (PD), there is evidence that environmental factors are also involved in the pathogenesis of the disease and that hydrocarbon-solvents may be one of them. The genetic component is less evident in late-onset PD. To assess whether age and PD may affect the catabolism of the hydrocarbon n-hexane, a two-part study was performed. In the first part the urinary levels of its main metabolites, 2,5-hexanedione and 2,5-dimethylpyrroles, were measured in 108 patients and 108 healthy controls, matched by age and sex. Metabolite urinary excretion was significantly reduced in PD patients as compared with controls and was inversely related to age in both groups. In the second part the same comparison was made between 24 non-smoking and 10 smoking patients, matched to controls, after smoking of a hydrocarbon-rich cigarette. In these subjects also n-hexane and 2,5-hexanedione blood levels were measured. There was no appreciable difference in n-hexane blood levels between patients and controls in non-smokers, whereas there was a significant increase in patients over controls in smokers (p < 0.01). 2,5-hexanedione blood levels were significantly lower in patients than in healthy controls, both in non-smokers and in smokers, but the reduction was more pronounced in smokers (-46.3 % versus -10.7 %). The same was true for 2,5-hexanedione and 2,5-dimethylpyrrole urinary levels. This study suggests that aging and PD may be associated with a reduction in the capacity to eliminate the hydrocarbon n-hexane. This metabolic alteration may play a role in the pathogenesis of PD.


Subject(s)
Hexanes/blood , Hexanes/urine , Parkinson Disease/blood , Parkinson Disease/urine , Age Factors , Aged , Analysis of Variance , Cohort Studies , Female , Humans , Male , Middle Aged
9.
Neurotoxicol Teratol ; 24(5): 621-8, 2002.
Article in English | MEDLINE | ID: mdl-12200193

ABSTRACT

Neuromelanin (NM) is a dark-coloured pigment produced in the dopaminergic neurons of the human substantia nigra (SN). The function of NM within the pigmented neurons is unknown but other melanins are believed to play a protective role via attenuation of free radical damage. Experimental evidence suggests that NM may also exhibit this characteristic, possibly by directly inactivating free radical species or via its ability to chelate transition metals, such as iron. Increased tissue iron, however, may saturate iron-chelating sites on NM and a looser association between iron and NM may result in an increased, rather than decreased, production of free radical species. The death of NM-pigmented neurons in Parkinson's disease (PD) is associated with both a measurable increase in tissue iron concentrations and indices of free radical mediated damage, suggesting that NM is involved in the aetiology of this disorder. As yet, it is unknown whether NM in the parkinsonian brain differs to that found in healthy tissue and thus may fulfil a different role within this tissue.


Subject(s)
Melanins/metabolism , Neurons/metabolism , Oxidative Stress/physiology , Parkinsonian Disorders/metabolism , Substantia Nigra/metabolism , Binding Sites/physiology , Cell Respiration/physiology , Dopamine/metabolism , Free Radicals/metabolism , Humans , Iron/metabolism , Parkinsonian Disorders/physiopathology , Substantia Nigra/physiopathology
10.
J Neural Transm (Vienna) ; 109(5-6): 663-72, 2002 May.
Article in English | MEDLINE | ID: mdl-12111458

ABSTRACT

Neuromelanin (NM) is a peculiar biochemical component of several neurons in the Substantia Nigra (SN), the target area of the degenerative process in Parkinson Disease (PD). SN NM has peculiarities as to its composition and an impressive capacity of chelating metals, iron in particular, but not exclusively. Gaining insights into the structural and functional characteristics of NM should help understanding the reasons of selective vulnerability of nigral neurons in many parkinsonian conditions. From the present data a protective role of NM can be postulated until the buffering capability toward heavy metals are exhausted. The overloading of NM with iron and other metals in neurons may trigger inflammatory and degenerative processes aggravating the underlying pathological condition.


Subject(s)
Melanins/physiology , Metals/pharmacology , Substantia Nigra/metabolism , Drug Interactions , Humans , Iron/pharmacology , Melanins/chemistry
11.
Mol Pathol ; 54(6): 414-8, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11724917

ABSTRACT

The pigmented neurones of the substantia nigra are typically lost in Parkinson's disease; however, the possible relation between neuronal vulnerability and the presence of neuromelanin has not been elucidated. Early histological studies revealed the presence of increasing amounts of neuromelanin in the substantia nigra with aging in higher mammals, showed that the neuromelanin granules are surrounded by a membrane, and comparatively evaluated the pigmentation of the substantia nigra in different animal species. Histochemical studies showed the association of neuromelanin with lipofuscins. However, systematic investigations of the structure, synthesis, and molecular interactions of neuromelanin have been undertaken only during the past decade. In these later studies, neuromelanin was identified as a genuine melanin with a strong chelating ability for iron and an affinity for compounds such as lipids, pesticides, and MPP(+). The affinity of neuromelanin for a variety of inorganic and organic toxins is consistent with a postulated protective function for neuromelanin. Moreover, the neuronal accumulation of neuromelanin during aging and the link between its synthesis and a high cytosolic concentration of catechols suggest a protective role. However, its putative neuroprotective effects could be quenched in conditions of toxin overload.


Subject(s)
Melanins/physiology , Parkinson Disease/metabolism , Substantia Nigra/metabolism , Aging/physiology , Animals , Cell Death , Chelating Agents/metabolism , Cholesterol/metabolism , Humans , Iron/metabolism , Lipid Metabolism , Locus Coeruleus/metabolism , Locus Coeruleus/pathology , Melanins/chemistry , Paraquat/metabolism , Parkinson Disease/pathology , Pesticides/metabolism , Substantia Nigra/pathology , Toxins, Biological/metabolism
12.
J Neurochem ; 79(2): 225-36, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11677250

ABSTRACT

A central role of iron in the pathogenesis of Parkinson's disease (PD), due to its increase in substantia nigra pars compacta dopaminergic neurons and reactive microglia and its capacity to enhance production of toxic reactive oxygen radicals, has been discussed for many years. Recent transcranial ultrasound findings and the observation of the ability of iron to induce aggregation and toxicity of alpha-synuclein have reinforced the critical role of iron in the pathogenesis of nigrostriatal injury. Presently the mechanisms involved in the disturbances of iron metabolism in PD remain obscure. In this review we summarize evidence from recent studies suggesting disturbances of iron metabolism in PD at possibly different levels including iron uptake, storage, intracellular metabolism, release and post-transcriptional control. Moreover we outline that the interaction of iron with other molecules, especially alpha-synuclein, may contribute to the process of neurodegeneration. Because many neurodegenerative diseases show increased accumulation of iron at the site of neurodegeneration, it is believed that maintenance of cellular iron homeostasis is crucial for the viability of neurons.


Subject(s)
Brain/metabolism , Iron/metabolism , Parkinson Disease/etiology , Animals , Brain/cytology , Homeostasis/physiology , Humans , Nerve Tissue Proteins/physiology , Neurons/metabolism , Protein Processing, Post-Translational , Synucleins , alpha-Synuclein
13.
Free Radic Biol Med ; 30(7): 803-8, 2001 Apr 01.
Article in English | MEDLINE | ID: mdl-11275480

ABSTRACT

Nitric oxide synthases (NOS) convert L-arginine and N(omega)-hydroxy-L-arginine to nitric oxide (*NO) and/or nitroxyl (NO(-)) in a NADPH-dependent fashion. Subsequently, *NO/superoxide (O(2-)-derived peroxynitrite (ONOO(-)) consumes one additional mol NADPH. The related stoichiometry of NO(-) and NADPH is unclear. We here describe that NO(-) also oxidizes NADPH in a concentration-dependent manner. In the presence of superoxide dismutase (SOD), which also converts NO(-) to *NO, nitrite accumulation was almost doubled and no oxidation of NADPH was observed. Nitrate yield from NO(-) was low, arguing against intermediate ONOO(-) formation. Thus, biologically formed NO(-) may function as an effective pro-oxidant unless scavenged by SOD and affect the apparent NADPH stoichiometry of the NOS reaction.


Subject(s)
NADP/metabolism , Nitrogen Oxides/metabolism , Superoxide Dismutase/metabolism , Free Radicals , Nitric Oxide Synthase/metabolism , Oxidants/metabolism , Oxidation-Reduction
14.
J Neurochem ; 76(6): 1766-73, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11259494

ABSTRACT

Information on the molecular distribution and ageing trend of brain iron in post-mortem material from normal subjects is scarce. Because it is known that neuromelanin and ferritin form stable complexes with iron(III), in this study we measured the concentration of iron, ferritin and neuromelanin in substantia nigra from normal subjects, aged between 1 and 90 years, dissected post mortem. Iron levels in substantia nigra were 20 ng/mg in the first year of life, had increased to 200 ng/mg by the fourth decade and remained stable until 90 years of age. The H-ferritin concentration was also very low (29 ng/mg) during the first year of life but increased rapidly to values of approximately 200 ng/mg at 20 years of age, which then remained constant until the eighth decade of life. L-Ferritin also showed an increasing trend during life although the concentrations were approximately 50% less than that of H-ferritin at each age point. Neuromelanin was not detectable during the first year, increased to approximately 1000 ng/mg in the second decade and then increased continuously to 3500 ng/mg in the 80th year. A Mössbauer study revealed that the high-spin trivalent iron is probably arranged in a ferritin-like iron--oxyhydroxide cluster form in the substantia nigra. Based on this data and on the low H- and L-ferritin content in neurones it is concluded that neuromelanin is the major iron storage in substantia nigra neurones in normal individuals.


Subject(s)
Aging/metabolism , Ferritins/metabolism , Iron/metabolism , Melanins/metabolism , Substantia Nigra/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Humans , Infant , Middle Aged , Nerve Degeneration/metabolism , Reference Values , Substantia Nigra/growth & development , Substantia Nigra/pathology
15.
Cancer Gene Ther ; 7(10): 1299-306, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11059686

ABSTRACT

Mutations in the CD40 ligand (CD40L) are responsible for human hyper immunoglobulin M (IgM) syndrome. The absence of the interaction between CD40L, expressed by T lymphocytes, and the CD40 receptor present on the surface of B cells is responsible for the inability of B cells to carry out the isotype switch from IgM to the other Ig classes. This leads to a fatal immunodeficiency for which no cure exists. For these reasons, the CD40L gene is a good candidate for gene therapy studies. To investigate the possible effects of the expression of this tightly regulated gene in vivo, we produced transgenic mice in which CD40L expression was deregulated. Widespread ectopic expression appears to be lethal. Overexpression in mature T cells is compatible with life, but in one-third of the cases, mice developed atypical lymphoid proliferations which, occasionally, progressed into frank lymphomas. Even though gene therapy is one of the most promising approaches to cure human hyper IgM syndrome, these results suggest that when we modify very tightly regulated genes such as cytokines or other growth factors, particular care has to be taken to avoid excessive stimulation of the target cells.


Subject(s)
CD40 Ligand/genetics , Genetic Therapy/methods , Hypergammaglobulinemia/therapy , Immunoglobulin M , Lymphoma, B-Cell/etiology , Animals , B-Lymphocytes/immunology , Blotting, Northern , CD40 Antigens/genetics , Cells, Cultured , DNA Primers/chemistry , Flow Cytometry , Gene Expression , Humans , Hypergammaglobulinemia/immunology , Immunoenzyme Techniques , Lymph Nodes/ultrastructure , Lymphocyte Activation , Lymphoma, B-Cell/immunology , Lymphoma, B-Cell/pathology , Mice , Mice, Transgenic , Polymerase Chain Reaction , T-Lymphocytes/immunology
16.
J Neurochem ; 75(6): 2583-9, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11080212

ABSTRACT

Neuromelanin (NM) is a complex polymer pigment found primarily in the dopaminergic neurons of the human substantia nigra. The structure of NM is only partially characterized, and its synthesis pathway remains unknown. We used nuclear magnetic and infrared spectroscopy to examine the structure of human NM isolated from the substantia nigra compared with synthetic dopamine melanins. Biochemical analyses were used to investigate proteinaceous and dopaminergic components in these samples. Following acid hydrolysis of NM samples, small amounts of DOPA, dopamine, and a variety of amino acids were measured. These findings suggest a peptide component in NM structure. NM also appears to contain a variety of unidentified structural components possibly derived from the oxidation of dopamine. Human NM differs structurally from synthetic dopamine melanin, but both human and synthetic NM include an aromatic backbone. It is interesting that both human NM and synthetic melanin also contain a large proportion of aliphatic structures. Our results suggest that NM is a more complex pigment than synthetic dopamine melanin formed via dopamine autoxidation alone.


Subject(s)
Dopamine/chemistry , Melanins/chemistry , Substantia Nigra/chemistry , Adult , Aged , Aged, 80 and over , Amino Acids/analysis , Dihydroxyphenylalanine/analysis , Germany , Humans , Hydrolysis , Italy , Magnetic Resonance Spectroscopy , Middle Aged , Molecular Structure
17.
Proc Natl Acad Sci U S A ; 97(22): 11869-74, 2000 Oct 24.
Article in English | MEDLINE | ID: mdl-11050221

ABSTRACT

Melanin, the pigment in hair, skin, eyes, and feathers, protects external tissue from damage by UV light. In contrast, neuromelanin (NM) is found in deep brain regions, specifically in loci that degenerate in Parkinson's disease. Although this distribution suggests a role for NM in Parkinson's disease neurodegeneration, the biosynthesis and function of NM have eluded characterization because of lack of an experimental system. We induced NM in rat substantia nigra and PC12 cell cultures by exposure to l-dihydroxyphenylalanine, which is rapidly converted to dopamine (DA) in the cytosol. This pigment was identical to human NM as assessed by paramagnetic resonance and was localized in double membrane autophagic vacuoles identical to NM granules of human substantia nigra. NM synthesis was abolished by adenoviral-mediated overexpression of the synaptic vesicle catecholamine transporter VMAT2, which decreases cytosolic DA by increasing vesicular accumulation of neurotransmitter. The NM is in a stable complex with ferric iron, and NM synthesis was inhibited by the iron chelator desferrioxamine, indicating that cytosolic DA and dihydroxyphenylalanine are oxidized by iron-mediated catalysis to membrane-impermeant quinones and semiquinones. NM synthesis thus results from excess cytosolic catecholamines not accumulated into synaptic vesicles. The permanent accumulation of excess catechols, quinones, and catechol adducts into a membrane-impermeant substance trapped in organelles may provide an antioxidant mechanism for catecholamine neurons. However, NM in organelles associated with secretory pathways may interfere with signaling, as it delays stimulated neurite outgrowth in PC12 cells.


Subject(s)
Catecholamines/physiology , Cytosol/metabolism , Melanins/biosynthesis , Synaptic Vesicles/metabolism , Animals , Catecholamines/metabolism , Electron Spin Resonance Spectroscopy , Nerve Growth Factors/metabolism , Neurons/metabolism , PC12 Cells , Rats , Rats, Sprague-Dawley , Substantia Nigra/cytology , Substantia Nigra/metabolism
18.
Exp Gerontol ; 35(5): 613-25, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10978683

ABSTRACT

We previously demonstrated that the rat thymus undergoes a progressive remodelling long before the appearance of typical signs of involution [Quaglino, D., Capri, M., Bergamini, G., Euclidi, E., Zecca, L., Franceschi, C., Pasquali Ronchetti, I., 1998. Age-dependent remodelling of rat thymus. Morphological and cytofluorimetric analysis from birth up to one year of age. Eur. J. Cell. Biol. 76, 156-166]. To focus better on the complex remodelling that occurs in the rat immune system during the first year of life, we analysed the phenotype profile of thymocytes, and T lymphocytes from mesenteric lymph nodes and peripheral blood of the same animals by flow cytometry. Two experimental sets were performed simultaneously using the same animal strain, but starting and ending the study at different ages (15 days up to 300 days in the first experimental set, and 90 days up to 360 days of life in the second). In the rat these ages appear to be crucial not only for developmental, maturative and early involutional processes of the thymus, but also of the entire immune system. The main findings were the following: (1) in the thymus, CD8(-)CD4(-) cells increased, CD5(+)alphabeta TCR(-) and CD8(+)CD4(+) thymocytes decreased, while the most mature cell subset appeared well preserved with ageing; (2) in the lymph nodes, T helper and T cytotoxic lymphocytes decreased in the most aged animals. Memory/activated CD4(+)CD45RC(-) T cells decreased, while naive/resting CD4(+)CD45RC(+) cells increased in the youngest animals and decreased in the oldest. CD8(+)CD45RC(-) and CD8(+)CD45RC(+) lymphocytes showed a complex age-dependent trend, and (3) in peripheral blood, minor modifications were evident, such as an age-dependent increase in the alphabeta TCR(+)CD25(+) cell subset. Some of these changes were related to the developmental process, while others could likely be interpreted as early signs of immunosenescence. The role of these modifications in immune system is discussed within the framework of the remodelling hypothesis of immunosenescence. The age-dependent changes in these three lymphoid compartments, however, appear to be different and only partially overlapping, thus suggesting that the maturational, developmental and ageing processes have distinct characteristics in the central and peripheral lymphoid organs.


Subject(s)
Lymph Nodes/immunology , T-Lymphocyte Subsets/immunology , Thymus Gland/immunology , Age Factors , Animals , Flow Cytometry , Immunophenotyping , Male , Rats , Rats, Sprague-Dawley
19.
Nat Genet ; 25(3): 343-6, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10888887

ABSTRACT

Osteopetrosis includes a group of inherited diseases in which inadequate bone resorption is caused by osteoclast dysfunction. Although molecular defects have been described for many animal models of osteopetrosis, the gene responsible for most cases of the severe human form of the disease (infantile malignant osteopetrosis) is unknown. Infantile malignant autosomal recessive osteopetrosis (MIM 259700) is a severe bone disease with a fatal outcome, generally within the first decade of life. Osteoclasts are present in normal or elevated numbers in individuals affected by autosomal recessive osteopetrosis, suggesting that the defect is not in osteoclast differentiation, but in a gene involved in the functional capacity of mature osteoclasts. Some of the mouse mutants have a decreased number of osteoclasts, which suggests that the defect directly interferes with osteoclast differentiation. In other mutants, it is the function of the osteoclast that seems to be affected, as they show normal or elevated numbers of non-functioning osteoclasts. Here we show that TCIRG1, encoding the osteoclast-specific 116-kD subunit of the vacuolar proton pump, is mutated in five of nine patients with a diagnosis of infantile malignant osteopetrosis. Our data indicate that mutations in TCIRG1 are a frequent cause of autosomal recessive osteopetrosis in humans.


Subject(s)
Osteopetrosis/genetics , Proton Pumps/genetics , Proton-Translocating ATPases/genetics , Vacuolar Proton-Translocating ATPases , Alternative Splicing , Base Sequence , Bone Marrow/pathology , DNA, Complementary , Exons , Female , Frameshift Mutation , Genes, Recessive , Humans , Infant , Introns , Male , Molecular Sequence Data , Osteopetrosis/pathology
20.
Cancer Res ; 60(10): 2660-5, 2000 May 15.
Article in English | MEDLINE | ID: mdl-10825138

ABSTRACT

The possibility to inhibit tumor growth by interfering with the formation of new vessels, which most neoplasias depend on, has recently raised considerable interest. An angiogenic switch, in which proliferating cells acquire the ability to direct new vessel formation, is thought to be an early step in the natural history of solid tumors. Using a transgenic model of breast cancer, which shows many similarities to its human counterpart, including ability to metastasize, we targeted angiostatin production to an early stage of tumor formation. Liposome-delivered angiostatin considerably delayed primary tumor growth and, more importantly, inhibited the appearance of lung metastases. These findings can be relevant to the design of therapeutic intervention in humans.


Subject(s)
Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Liposomes , Mammary Neoplasms, Experimental/drug therapy , Neoplasm Metastasis/prevention & control , Peptide Fragments/administration & dosage , Peptide Fragments/therapeutic use , Plasminogen/administration & dosage , Plasminogen/therapeutic use , Angiostatins , Animals , Female , Genetic Therapy , Humans , Mammary Neoplasms, Experimental/pathology , Membrane Proteins/genetics , Mice , Mice, Transgenic , Receptor, ErbB-2/genetics , Receptors, Virus/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...